Wordt geladen...
LCZ696, a First‐in‐Class Angiotensin Receptor‐Neprilysin Inhibitor: The First Clinical Experience in Patients With Severe Hypertension
The safety of LCZ696, a novel angiotensin receptor‐neprilysin inhibitor, was evaluated for the first time in patients with severe hypertension in this 8‐week, multicenter, open‐label study. Thirty‐five Japanese patients with either office systolic blood pressure (SBP) ≥180 mm Hg or diastolic blood p...
Bewaard in:
| Gepubliceerd in: | J Clin Hypertens (Greenwich) |
|---|---|
| Hoofdauteurs: | , , , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
John Wiley and Sons Inc.
2015
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8032009/ https://ncbi.nlm.nih.gov/pubmed/26402918 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/jch.12667 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|